财务数据和关键指标变化 - 第一季度收入为457,000美元,包括Platinum仪器、耗材试剂和相关服务收入 [47] - 毛利为269,000美元,毛利率为59%。毛利率在短期内会有一定波动,受初期商业化阶段和存货成本调整的影响 [48][49][50][51] - 经调整的营业费用为21.9百万美元,同比下降2.7百万美元,主要来自研发费用的下降 [52][53][54] - 净亏损为19.5百万美元,同比下降4.1百万美元,主要由于营业费用下降 [55] - 经调整EBITDA为-20.5百万美元,同比改善3.2百万美元 [56] - 截至3月31日,现金及等价物和有价证券投资为235.4百万美元 [57] 各条业务线数据和关键指标变化 - 公司已完成全面商业化发布,并成功将所有现有客户迁移至版本2试剂盒 [13][14] - 版本2试剂盒获得客户积极反馈,包括提高了肽段比对数量、未知蛋白识别精度,以及分析时间大幅缩短 [32][33] - 公司正在开发版本3试剂盒,预计将于2024年第三季度交付客户,性能将较版本2有大幅提升 [36][37] 各个市场数据和关键指标变化 - 公司在美国采取直销模式,在欧洲采取直销和分销相结合的方式,在日本通过分销商进入亚太市场 [16][17] - 截至第一季度末,公司直销团队约24人,覆盖美国和西欧 [17] - 公司在学术研究、政府和制药行业等市场均获得首批客户,显示技术广泛应用前景 [20][24][25] - 公司密切关注销售周期和资本预算环境,目前未受到显著影响 [26][27] 公司战略和发展方向及行业竞争 - 公司2024年三大优先事项为:加速商业化、交付创新路线图、保持财务实力 [10][11] - 公司将继续扩大直销和分销团队,密切监控商业指标,根据需求灵活调整 [14][19][29][30] - 公司将持续推进技术创新,如版本2和版本3试剂盒的开发,以及分析软件的升级 [31][32][33][36][37][38][40] - 公司参加行业会议并支持客户演讲,提高技术知名度和应用拓展 [41][42] 管理层对经营环境和未来前景的评论 - 公司对商业化全面启动后的稳定增长充满信心,将密切监控并适时扩大团队 [14][29][30] - 公司看好政府、制药等新兴市场的长期潜力,但认为短期内仍需更多时间培养 [64][65][66][67] - 公司认为软件分析是未来重点发展方向,将推出针对性工具以满足不同客户需求 [83][84][85] 问答环节重要的提问和回答 问题1 **Swayampakula Ramakanth 提问** 对公司商业化全面启动后的进展情况及2024年全年收入指引的信心来源 [61][62][63] **Jeff Hawkins 回答** 公司将在Q2保持相对温和的增长,随着新销售团队逐步成熟,预计下半年将加速增长,从而实现全年收入指引 [62][63] 问题2 **Swayampakula Ramakanth 提问** 政府和制药行业客户的获取情况及未来发展前景 [64][65] **Jeff Keyes 回答** 这些新兴市场客户的销售周期相对较长,公司正在积累经验,未来会继续拓展这些领域 [65][66][67] 问题3 **Kyle Mikson 提问** 公司软件分析产品的定位及未来发展方向 [83][84][85] **Jeff Hawkins 回答** 公司将在通用分析工具的基础上,开发针对性更强的定制化分析工具,满足不同客户需求 [83][84][85]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Former name, former address and former fiscal year, if changed since last report) Securities registered pursuant to Section 12(b) of the Act: For the transition period from ________ to ___ ...

Exhibit 99.1 Quantum-Si Reports First Quarter 2024 Financial Results Executed Full Commercial Launch of Platinum® Instrument Reaf irms Full Year 2024 Financial Guidance BRANFORD, Conn. -- (BUSINESS WIRE) – May 9, 2024 -- Quantum-Si Incorporated (Nasdaq: QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing CompanyTM, today announced financial results for the first quarter ended March 31, 2024. Press Release Highlights "We concluded our first quarter of 2024 with great momentum on all fronts, i ...

Quantum-Si Incorporated (NASDAQ:QSI) Q4 2023 Earnings Conference Call February 29, 2024 4:30 PM ET Company Participants Katherine Atkinson – Senior Vice President-Commercial Marketing Jeff Hawkins – President and Chief Executive Officer Jeff Keyes – Chief Financial Officer Conference Call Participants Swayampakula Ramakanth – H.C. Wainwright Operator Good day, ladies and gentlemen. Thank you for standing by. Welcome to the Quantum-Si Fourth Quarter and Full Year 2023 Earnings Call. At this time, all partici ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39486 QUANTUM-SI INCORPORATED (Exact name of registrant as specified in its charter) Delaware 85-1388175 (State or other jurisdiction of incorp ...

Exhibit 99.1 Quantum-Si Reports Fourth Quarter and Full Year 2023 Financial Results Finalizing Commercial Readiness for Expected Full Commercial Launch by the End of Q1 2024 Releases Full Year 2024 Financial Guidance BRANFORD, Conn. -- (BUSINESS WIRE) – Feb. 29, 2024 -- Quantum-Si Incorporated (Nasdaq: QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing CompanyTM, today announced financial results for the fourth quarter and full year ended December 31, 2023. Press Release Highlights "We made ...

Quantum-Si Incorporated (NASDAQ:QSI) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ET Company Participants Katherine Atkinson - SVP, Commercial Marketing Jeff Hawkins - President and Chief Executive Officer Jeff Keyes - Chief Financial Officer Conference Call Participants Kyle Mikson - Canaccord Genuity Swayampakula Ramakanth - H.C. Wainwright Operator Good day and thank you for standing by. Welcome to the Quantum-Si Q3 2023 Earnings Call. At this time, all participants are in a listen-only mode ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to _________ Commission File Number: 001-39486 QUANTUM-SI INCORPORATED (Exact name of registrant as specified in its charter) Delaware 85-1388175 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to _________ Commission File Number: 001-39486 QUANTUM-SI INCORPORATED (Exact name of registrant as specified in its charter) Delaware 85-1388175 (Sta ...

Quantum-Si incorporated (NASDAQ:QSI) Q2 2023 Earnings Conference Call August 7, 2023 8:30 AM ET Company Participants Juan Avendano - Head, Investor Relations Jeff Hawkins - Chief Executive Officer Jeff Keyes - Chief Financial Officer Conference Call Participants Kyle Mikson - Canaccord Genuity Yuan Zhi - B. Riley Swayampakula Ramakanth - H.C. Wainwright Operator Ladies and gentlemen, thank you for standing by. Welcome to the Quantum-Si Second Quarter 2023 Earnings Call. [Operator Instructions] Please be ad ...